Ibandronate is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis. Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. Men should not take ibandronate unless they are participating in clinical trials. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.
-K725.gif)